With potential for re-dosing, Carmine’s gene therapy tech attracts Takeda as partner

Carmine’s non-viral gene therapy delivery technology offers manufacturing, dosing advantages

Carmine is developing red blood cell-based vesicles to deliver gene therapies, offering immunogenicity and manufacturing advantages over viral vector systems. The platform, which offers the potential for re-dosable gene therapies, led Takeda to become Carmine’s first partner Tuesday as the pharma pursues non-viral delivery technologies for pediatric rare genetic diseases.

Carmine Therapeutics Inc. was formed in 2019 with an exclusive license to its foundational vesicle technology that was developed

Read the full 692 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers